GSK executives acquire shares via reward plan | GSK SEC Filing

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

Form 6-K

 

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR
15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

 

 

 

For the
month of August 2026

 

Commission
File Number 001-15170

 

 

GSK plc

(Translation
of registrant’s name into English)

 

 

79 New Oxford Street, London, WC1A 1DG

(Address
of principal executive office)

 

 

 

Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.

 

Form
20-F . . . .X. . . . Form 40-F . . . . . . . .

 

 

 

 

GSK plc (the ‘Company’)

 

 

Transaction notification

 

1.

Details of PDMR/person closely associated with them
(‘PCA’)

 

a)

Name

Lynn Baxter

 

b)

Position/status

President, Europe

 

c)

Initial
notification/amendment

 

Initial notification

2.

Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor

 

a)

Name

GSK plc

 

b)

LEI

5493000HZTVUYLO1D793

 

3.

Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted

 

a)

Description
of the financial instrument

Ordinary shares of 31 ¼ pence each (‘Ordinary
Shares’)

 

ISIN: GB00BN7SWP63

 

b)

Nature
of the transaction

Acquisition of Ordinary Shares under the Company’s Share
Reward Plan

 

c)

Price(s)
and volume(s)

Price(s)

 

Volume(s)

£19.3496

 

7 (partnership shares)

£19.3496

 

7 (matching shares)

d)

Aggregated
information

 

 

Aggregated
volume Price

14 Ordinary Shares

 

£19.3496 

 

e)

Date
of the transaction

2026-08-11

 

f)

Place
of the transaction

 

London Stock Exchange (XLON)

 

 

1.

Details of PDMR/person closely associated with them
(‘PCA’)

 

a)

Name

Julie Brown

 

b)

Position/status

Chief
Financial Officer

 

c)

Initial
notification/amendment

 

Initial notification

2.

Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor

 

a)

Name

GSK plc

 

b)

LEI

5493000HZTVUYLO1D793

 

3.

Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted

 

a)

Description
of the financial instrument

Ordinary shares of 31 ¼ pence each (‘Ordinary
Shares’)

 

ISIN: GB00BN7SWP63

 

b)

Nature
of the transaction

Acquisition of Ordinary Shares under the Company’s Share
Reward Plan

 

c)

Price(s)
and volume(s)

Price(s)

 

Volume(s)

£19.3496

 

7 (partnership shares)

£19.3496

 

7 (matching shares)

d)

Aggregated
information

 

 

Aggregated
volume Price

14 Ordinary Shares

 

£19.3496

 

e)

Date
of the transaction

2026-08-11

 

f)

Place
of the transaction

 

London Stock Exchange (XLON)

 

 

1.

Details of PDMR/person closely associated with them
(‘PCA’)

 

a)

Name

James Ford

 

b)

Position/status

SVP and
Group General Counsel, Legal and Compliance

 

c)

Initial
notification/amendment

 

Initial notification

2.

Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor

 

a)

Name

GSK plc

 

b)

LEI

5493000HZTVUYLO1D793

 

3.

Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted

 

a)

Description
of the financial instrument

Ordinary shares of 31 ¼ pence each (‘Ordinary
Shares’)

 

ISIN: GB00BN7SWP63

 

b)

Nature
of the transaction

Acquisition of Ordinary Shares under the Company’s Share
Reward Plan

 

c)

Price(s)
and volume(s)

Price(s)

 

Volume(s)

£19.3496 

 

7 (partnership shares)

£19.3496

 

7 (matching shares)

d)

Aggregated
information

 

 

Aggregated
volume Price

14 Ordinary Shares

 

£19.3496

 

e)

Date
of the transaction

2026-08-11

 

f)

Place
of the transaction

 

London Stock Exchange (XLON)

 

 

1.

Details of PDMR/person closely associated with them
(‘PCA’)

 

a)

Name

David Redfern

 

b)

Position/status

President,
Corporate Development

 

c)

Initial
notification/amendment

 

Initial notification

2.

Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor

 

a)

Name

GSK plc

 

b)

LEI

5493000HZTVUYLO1D793

 

3.

Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted

 

a)

Description
of the financial instrument

Ordinary shares of 31 ¼ pence each (‘Ordinary
Shares’)

 

ISIN: GB00BN7SWP63

 

b)

Nature
of the transaction

Acquisition of Ordinary Shares under the Company’s Share
Reward Plan

 

c)

Price(s)
and volume(s)

Price(s)

 

Volume(s)

£19.3496

 

7 (partnership shares)

£19.3496

 

7 (matching shares)

d)

Aggregated
information

 

 

Aggregated
volume Price

14 Ordinary Shares

 

£19.3496

 

e)

Date
of the transaction

2026-08-11

 

f)

Place
of the transaction

 

London Stock Exchange (XLON)

 

 

1.

Details of PDMR/person closely associated with them
(‘PCA’)

 

a)

Name

Regis Simard

 

b)

Position/status

President,
Global Supply Chain

 

c)

Initial
notification/amendment

 

Initial notification

2.

Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor

 

a)

Name

GSK plc

 

b)

LEI

5493000HZTVUYLO1D793

 

3.

Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted

 

a)

Description
of the financial instrument

Ordinary shares of 31 ¼ pence each (‘Ordinary
Shares’)

 

ISIN: GB00BN7SWP63

 

b)

Nature
of the transaction

Acquisition of Ordinary Shares under the Company’s Share
Reward Plan

 

c)

Price(s)
and volume(s)

Price(s)

 

Volume(s)

£19.3496

 

7 (partnership shares)

£19.3496

 

7 (matching shares)

d)

Aggregated
information

 

 

Aggregated
volume Price

14 Ordinary Shares

 

£19.3496

 

e)

Date
of the transaction

2026-08-11

 

f)

Place
of the transaction

 

London Stock Exchange (XLON)

 

 

1.

Details of PDMR/person closely associated with them
(‘PCA’)

 

a)

Name

Philip Thomson

 

b)

Position/status

President,
Global Affairs

 

c)

Initial
notification/amendment

 

Initial notification

2.

Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor

 

a)

Name

GSK plc

 

b)

LEI

5493000HZTVUYLO1D793

 

3.

Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted

 

a)

Description
of the financial instrument

Ordinary shares of 31 ¼ pence each (‘Ordinary
Shares’)

 

ISIN: GB00BN7SWP63

  

b)

Nature
of the transaction

Acquisition of Ordinary Shares under the Company’s Share
Reward Plan

 

c)

Price(s)
and volume(s)

Price(s)

 

Volume(s)

£19.3496

 

7 (partnership shares)

£19.3496

 

7 (matching shares)

d)

Aggregated
information

 

 

Aggregated
volume Price

14 Ordinary Shares

 

£19.3496

 

e)

Date
of the transaction

2026-08-11

 

f)

Place
of the transaction

 

London Stock Exchange (XLON)

 

 

1.

Details of PDMR/person closely associated with them
(‘PCA’)

 

a)

Name

 

Deborah Waterhouse

b)

Position/status

 

CEO,
ViiV Healthcare and President, Global Health, GSK

c)

Initial
notification/amendment

 

Initial notification

2.

Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor

 

a)

Name

GSK plc

 

b)

LEI

5493000HZTVUYLO1D793

 

3.

Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted

 

a)

Description
of the financial instrument

Ordinary shares of 31 ¼ pence each (‘Ordinary
Shares’)

 

ISIN: GB00BN7SWP63

 

b)

Nature
of the transaction

Acquisition of Ordinary Shares under the Company’s Share
Reward Plan

 

c)

Price(s)
and volume(s)

Price(s)

 

Volume(s)

£19.3496

 

7 (partnership shares)

£19.3496

 

7 (matching shares)

d)

Aggregated
information

 

 

Aggregated
volume Price

14 Ordinary Shares

 

£19.3496

 

e)

Date
of the transaction

2026-08-11

 

f)

Place
of the transaction

 

London Stock Exchange (XLON)

 

 

1.

Details of PDMR/person closely associated with them
(‘PCA’)

 

a)

Name

Victoria Whyte

 

b)

Position/status

SVP
& Company Secretary

 

c)

Initial
notification/amendment

 

Initial notification

2.

Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor

 

a)

Name

GSK plc

 

b)

LEI

5493000HZTVUYLO1D793

 

3.

Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted

 

a)

Description
of the financial instrument

Ordinary shares of 31 ¼ pence each (‘Ordinary
Shares’)

 

ISIN: GB00BN7SWP63

 

b)

Nature
of the transaction

Acquisition of Ordinary Shares under the Company’s Share
Reward Plan

 

c)

Price(s)
and volume(s)

Price(s)

 

Volume(s)

£19.3496

 

6 (partnership shares)

£19.3496

 

6 (matching shares)

d)

Aggregated
information

 

 

Aggregated
volume Price

12 Ordinary Shares

 

£19.3496

 

e)

Date
of the transaction

2026-08-11

 

f)

Place
of the transaction

 

London Stock Exchange (XLON)

 

 

1.

Details of PDMR/person closely associated with them
(‘PCA’)

 

a)

Name

Neil Falkingham

 

b)

Position/status

PCA of Lynn Baxter (President, Europe)

 

c)

Initial
notification/amendment

 

Initial notification

2.

Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor

 

a)

Name

GSK plc

 

b)

LEI

5493000HZTVUYLO1D793

 

3.

Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted

 

a)

Description
of the financial instrument

Ordinary shares of 31 ¼ pence each (‘Ordinary
Shares’)

 

ISIN: GB00BN7SWP63

 

b)

Nature
of the transaction

Acquisition of Ordinary Shares under the Company’s Share
Reward Plan

 

c)

Price(s)
and volume(s)

Price(s)

 

Volume(s)

£19.3496

 

7 (partnership shares)

£19.3496

 

7 (matching shares)

d)

Aggregated
information

 

 

Aggregated
volume Price

14 Ordinary Shares

 

£19.3496

 

e)

Date
of the transaction

 

2026-08-11

f)

Place
of the transaction

 

London Stock Exchange (XLON)

 

 

About GSK

GSK is
a global biopharma company with a purpose to unite science,
technology, and talent to get ahead of disease together. Find out
more at www.gsk.com.

 

 

Registered
in England & Wales:

No.
3888792

 

 

Registered
Office:

79 New
Oxford Street

London

WC1A
1DG

 

 

SIGNATURES

 

 

Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorised.

 

GSK plc

 

(Registrant)

 

 

Date: August
13, 2026

 

 

 

 

By:/s/ VICTORIA
WHYTE

————————–

 

 

 

Victoria Whyte

 

Authorised
Signatory for and on

 

behalf
of GSK plc